Skip to content

Apremilast in psoriasis patients

Evaluating safety and effectiveness of Apremilast in Psoriasis in Iranian Adults

Status
Recruiting
Phases
Phase 4
Study type
Interventional
Source
IRCT
Registry ID
IRCT20240420061533N1
Enrollment
683
Registered
2025-04-26
Start date
2025-05-03
Completion date
Unknown
Last updated
2025-07-21

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Psoriasis. Psoriasis

Interventions

Control group: All patients admitted with a diagnosis of psoriasis will take the drug Apermilast from Abidi Pharmaceutical Company. This drug comes in a starter pack of tablets with doses of 10, 20, a

Sponsors

Cobel Darou
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to No maximum

Inclusion criteria

Inclusion criteria: Adults 18 years of age and older The definitive diagnosis of Psoriasis based on NPS criteria

Exclusion criteria

Exclusion criteria: Severe hypersensitivity to Apremilast Using of Apremilast in the past 3 months Active TB or incompletely treated infection Acute hepatic and renal failure Pregnancy and breastfeeding

Design outcomes

Primary

MeasureTime frame
Occurrence of serious adverse events. Timepoint: Month 2, Month 4, and Month 6 from the baseline of treatment. Method of measurement: Side effects questionnaire.

Secondary

MeasureTime frame
Psoriasis Area and Severity Index (PASI). Timepoint: Month 4 and Month 6 from the baseline of treatment. Method of measurement: PASI (Psoriasis Area and Severity Index) questionnaire.;Assessment of weight loss. Timepoint: Month 6 from the baseline of treatment. Method of measurement: BMI Index.;Discontinuation Rate due to AEs. Timepoint: Anytime during the study. Method of measurement: Side effects questionnaire.

Countries

Iran (Islamic Republic of)

Contacts

Public ContactAnahita Rahafrouz

Cobel Darou

CD.studies@cobeldarou.com+98 21 8864 9904

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026